European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

MAgnetically steerable wireless Nanodevices for the tarGeted delivery of therapeutIc agents in any vascular rEgion of the body

Descripción del proyecto

Unos dispositivos diminutos administran fármacos justo donde se necesita

¡No se deje engañar por el pequeño tamaño! Los dispositivos magnéticos diminutos tienen un potencial enorme para futuras aplicaciones biomédicas. Sin embargo, el uso de estos micro y nanodispositivos en entornos clínicos no es sencillo. El proyecto ANGIE, financiado con fondos europeos, forjará el futuro con pequeños dispositivos robóticos, sistemas de navegación magnéticos y administración selectiva y localizada de fármacos. En concreto, el proyecto desarrollará unos nanodispositivos inalámbricos orientables magnéticamente para la administración de agentes terapéuticos de manera selectiva a través del sistema vascular del cuerpo. Al crear una línea base de conocimientos y capacidades para la administración selectiva de fármacos, el proyecto mejorará la capacidad de los profesionales sanitarios de tratar múltiples enfermedades crónicas. Además, facilitará que los facultativos administren fármacos exactamente donde se necesite con unos efectos secundarios mínimos.

Objetivo

The past decade has seen exciting progress in the field of mobile magnetic small-scale devices. These tiny machines have demonstrated great potential for biomedical applications. However, current mobile micro- and nanodevices do not meet the conditions for their translation into medical practice. The use of these devices in clinical settings implies specific requirements and constraints that are often conflicting and imply substantial challenges that are not considered in lab-scale research. The ANGIE project puts forward a radically new technology that is far beyond the current state of the art in the field of micro/nanorobots, and implies major progress in small-scale robotics, magnetic navigation systems, and localized targeted drug delivery. ANGIE will create a solid baseline of knowledge and skills for localised targeted drug delivery based on steerable wireless nanodevices, capable of navigating the body vascular system to deliver drugs where no other instrument can go. ANGIE will offer health professionals vastly improved intervention capacity to tackle multiple chronic diseases and enable them to deliver drugs precisely where needed, with minimal side effects. To assemble the interdisciplinary communities around this technology and to demonstrate its potential to mitigate the impact of chronic health conditions, we will apply the ANGIE technology for the localized treatment of thrombotic stroke. ANGIE is supported by stakeholders representing a broad spectrum of European organizations and citizens, such as large multinationals (e.g. Siemens and CLS Behring), policy makers (e.g. health systems and healthcare facilities), as well as civil society organizations (e.g. associations of health professionals and stroke patients). These stakeholders will help us create an innovation eco-system around our radically new technology and will play vital advisory roles regarding the feasibility, transferability, and exploitability of the proposed technology.

Convocatoria de propuestas

H2020-FETPROACT-2019-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-EIC-FETPROACT-2019

Régimen de financiación

RIA - Research and Innovation action

Coordinador

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Aportación neta de la UEn
€ 850 000,00
Dirección
Raemistrasse 101
8092 Zuerich
Suiza

Ver en el mapa

Región
Schweiz/Suisse/Svizzera Zürich Zürich
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 850 000,00

Participantes (8)